Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors
That is an 18% lower risk of blood clots in the GLP-1 group
Preparing for Success with AOD-9604 Proper preparation for AOD-9604 therapy involves much more than simply ordering the peptide and starting injections
9% placebo) 20% weight loss: 45% of participants (vs
Watch now on iPlayer Wegovy's manufacturer, Novo Nordisk, said that treatment decisions should be made together with a healthcare provider and that "side effects should be taken into account as part of this"
While this is lower than injectable semaglutide or tirzepatide, orforglipron offers: No food timing restrictions No SNAC absorption enhancer needed Stable at room temperature Simple once-daily dosing Non-peptide structure (easier manufacturing) The ATTAIN program includes studies in T2D (ATTAIN-2), cardiovascular outcomes, and combinations
US$ 27.80
US$ 27.02
US$ 25.64
US$ 29.51
